CA3254865A1 - Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders - Google Patents
Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disordersInfo
- Publication number
- CA3254865A1 CA3254865A1 CA3254865A CA3254865A CA3254865A1 CA 3254865 A1 CA3254865 A1 CA 3254865A1 CA 3254865 A CA3254865 A CA 3254865A CA 3254865 A CA3254865 A CA 3254865A CA 3254865 A1 CA3254865 A1 CA 3254865A1
- Authority
- CA
- Canada
- Prior art keywords
- ganaxolone
- cyclodextrin
- status epilepticus
- formulation
- sulfobutyl ether
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562112943P | 2015-02-06 | 2015-02-06 | |
| US62/112,943 | 2015-02-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2973140A Division CA2973140C (en) | 2015-02-06 | 2016-02-08 | Intravenous Ganaxolone Formulations and Their Use in the Treatment of Status Epilepticus and Other Epileptic Disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3254865A1 true CA3254865A1 (en) | 2025-05-28 |
Family
ID=56564813
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3254865A Pending CA3254865A1 (en) | 2015-02-06 | 2016-02-08 | Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders |
| CA2973140A Active CA2973140C (en) | 2015-02-06 | 2016-02-08 | Intravenous Ganaxolone Formulations and Their Use in the Treatment of Status Epilepticus and Other Epileptic Disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2973140A Active CA2973140C (en) | 2015-02-06 | 2016-02-08 | Intravenous Ganaxolone Formulations and Their Use in the Treatment of Status Epilepticus and Other Epileptic Disorders |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20160228454A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4059522A1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP2018504420A (cg-RX-API-DMAC7.html) |
| CN (3) | CN115381772A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016214996B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3254865A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL302203A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016127170A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ773177A (en) | 2012-01-23 | 2022-09-30 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| EP2887944B1 (en) | 2012-08-21 | 2021-10-06 | Sage Therapeutics, Inc. | Allopregnanolone for treating refractory status epilepticus |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| JP2018504420A (ja) * | 2015-02-06 | 2018-02-15 | マリナス ファーマシューティカルズ インコーポレイテッド | 静注用ガナキソロン製剤ならびにてんかん重積状態および他の発作性障害の治療におけるその使用 |
| MA45276A (fr) * | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| CA3001722A1 (en) | 2015-10-16 | 2017-04-20 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| US20170174614A1 (en) | 2015-12-22 | 2017-06-22 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| FI3800177T3 (fi) | 2015-12-22 | 2025-04-29 | Zogenix International Ltd | Fenfluramiinikoostumukset ja menetelmät niiden valmistamiseksi |
| CA3158448A1 (en) | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| EP3481387A4 (en) | 2016-08-11 | 2020-04-08 | Ovid Therapeutics Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF EPLEPTIC DISORDERS |
| EP4201427A1 (en) | 2016-08-24 | 2023-06-28 | Zogenix International Limited | Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| WO2018071803A1 (en) * | 2016-10-14 | 2018-04-19 | Marinus Pharmaceuticals, Inc | Method of administering a neurosteroid to effect electroencephalographic (eeg) burst suppression |
| CA3043626A1 (en) * | 2016-11-22 | 2018-05-31 | Ovid Therapeutics Inc. | Methods of treating attention deficit/hyperactivity disorder with gaboxadol |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| EA202091144A1 (ru) * | 2017-11-10 | 2020-09-16 | Маринус Фармасьютикалз, Инк. | Ганаксолон для использования в лечении наследственных эпилептических заболеваний |
| CN108535398B (zh) * | 2018-04-04 | 2020-03-27 | 福州海王福药制药有限公司 | 一种采用反相高效液相色谱法分离盐酸噻加宾手性对映体的方法 |
| US11571397B2 (en) | 2018-05-11 | 2023-02-07 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| US10517841B1 (en) | 2018-06-14 | 2019-12-31 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
| EP3860595A4 (en) * | 2018-11-05 | 2021-11-10 | Ovid Therapeutics Inc. | USE OF GABOXADOL, GANAXOLONE, AND ALLOPREGNANOLONE TO TREAT MOTION DISORDERS |
| CA3117868A1 (en) | 2018-11-19 | 2020-05-28 | Zogenix International Limited | Methods of treating rett syndrome using fenfluramine |
| WO2020118142A1 (en) | 2018-12-07 | 2020-06-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of pospartum depression |
| MA54460A (fr) | 2018-12-14 | 2021-10-20 | Eisai R&D Man Co Ltd | Formulations pharmaceutiques à base d'eau de composés de 1,2-dihydropyridine |
| WO2020157257A1 (en) * | 2019-02-01 | 2020-08-06 | H. Lundbeck A/S | Injectable carbamazepine composition essentially free of 10-br-carbamazepine |
| US10959962B2 (en) * | 2019-02-15 | 2021-03-30 | Saol International Development Ltd. | Injectable phenol formulations and methods of their use |
| JP2022521446A (ja) * | 2019-02-25 | 2022-04-07 | ゾゲニクス インターナショナル リミテッド | 発作制御を改善するための製剤 |
| US20210260074A1 (en) * | 2019-04-29 | 2021-08-26 | Marsh and Wang Medical Systems, LLC | Seizure control compositions and methods of using same |
| US20200338090A1 (en) * | 2019-04-29 | 2020-10-29 | Marsh and Wang Medical Systems, LLC | Seizure control compositions and methods of using same |
| KR20220006565A (ko) | 2019-05-10 | 2022-01-17 | 브리 바이오사이언시스, 인크. | 브렉사놀론, 가낙솔론, 또는 주라놀론을 함유하는 약제 조성물, 및 이것의 용도 |
| EP4009982A4 (en) * | 2019-08-05 | 2023-08-09 | Marinus Pharmaceuticals, Inc. | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS |
| CN119950517A (zh) | 2019-12-06 | 2025-05-09 | 马瑞纳斯制药公司 | 用于治疗结节性硬化症的加奈索酮 |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| WO2022109440A1 (en) * | 2020-11-23 | 2022-05-27 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treatment of super refractory status epilepticus |
| EP4255438A4 (en) * | 2020-12-07 | 2024-10-16 | Marinus Pharmaceuticals, Inc. | USE OF GANAXOLONE IN THE TREATMENT OF AN EPILEPTIC DISORDER |
| WO2023060020A1 (en) * | 2021-10-04 | 2023-04-13 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treatment of established status epilepticus |
| CN114272216B (zh) * | 2021-10-11 | 2023-07-04 | 浙江歌文达生物医药科技有限公司 | 一种2-氧代-1-吡咯烷衍生物的冻干制剂及其制备 |
| CN116769070B (zh) * | 2023-06-07 | 2025-07-01 | 浙江工业大学 | 一种功能化磁性纳米颗粒及作为手性萃取剂在液-液萃取拆分手性化合物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| NZ568700A (en) * | 2005-11-28 | 2012-03-30 | Marinus Pharmaceuticals | Solid stabilized particulate formulations comprising ganaxolone |
| EP2525798B1 (en) * | 2010-01-21 | 2017-08-09 | Drawbridge Pharmaceuticals Pty Ltd. | Anaesthetic formulation |
| EP2887944B1 (en) * | 2012-08-21 | 2021-10-06 | Sage Therapeutics, Inc. | Allopregnanolone for treating refractory status epilepticus |
| AU2013352141B2 (en) * | 2012-11-30 | 2018-04-05 | The Regents Of The University Of California | Anticonvulsant activity of steroids |
| JOP20200195A1 (ar) * | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| JP2018504420A (ja) * | 2015-02-06 | 2018-02-15 | マリナス ファーマシューティカルズ インコーポレイテッド | 静注用ガナキソロン製剤ならびにてんかん重積状態および他の発作性障害の治療におけるその使用 |
| US10391105B2 (en) * | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
-
2016
- 2016-02-08 JP JP2017540743A patent/JP2018504420A/ja active Pending
- 2016-02-08 CN CN202211150855.3A patent/CN115381772A/zh active Pending
- 2016-02-08 AU AU2016214996A patent/AU2016214996B2/en active Active
- 2016-02-08 CN CN201680008938.5A patent/CN107427458A/zh active Pending
- 2016-02-08 CA CA3254865A patent/CA3254865A1/en active Pending
- 2016-02-08 EP EP22152108.1A patent/EP4059522A1/en active Pending
- 2016-02-08 CA CA2973140A patent/CA2973140C/en active Active
- 2016-02-08 WO PCT/US2016/016977 patent/WO2016127170A1/en not_active Ceased
- 2016-02-08 CN CN202211152228.3A patent/CN115487313A/zh active Pending
- 2016-02-08 IL IL302203A patent/IL302203A/en unknown
- 2016-02-08 EP EP16706109.2A patent/EP3253418A1/en not_active Withdrawn
- 2016-02-08 US US15/018,258 patent/US20160228454A1/en not_active Abandoned
- 2016-02-08 IL IL252848A patent/IL252848B2/en unknown
-
2021
- 2021-07-02 JP JP2021110619A patent/JP7273897B2/ja active Active
-
2023
- 2023-03-17 JP JP2023042531A patent/JP7566961B2/ja active Active
- 2023-03-28 US US18/191,445 patent/US20230293549A1/en not_active Abandoned
- 2023-09-21 US US18/472,048 patent/US20240016817A1/en not_active Abandoned
-
2024
- 2024-10-02 JP JP2024173821A patent/JP2024178469A/ja not_active Withdrawn
- 2024-12-20 US US18/989,280 patent/US20250325562A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115381772A (zh) | 2022-11-25 |
| CA2973140A1 (en) | 2016-08-11 |
| IL252848B2 (en) | 2024-07-01 |
| US20160228454A1 (en) | 2016-08-11 |
| CA2973140C (en) | 2025-09-16 |
| IL252848B1 (en) | 2024-03-01 |
| JP2021155457A (ja) | 2021-10-07 |
| JP2024178469A (ja) | 2024-12-24 |
| US20240016817A1 (en) | 2024-01-18 |
| IL252848A0 (en) | 2017-08-31 |
| CN107427458A (zh) | 2017-12-01 |
| WO2016127170A1 (en) | 2016-08-11 |
| AU2016214996A1 (en) | 2017-06-29 |
| JP7273897B2 (ja) | 2023-05-15 |
| US20250325562A1 (en) | 2025-10-23 |
| JP7566961B2 (ja) | 2024-10-15 |
| CN115487313A (zh) | 2022-12-20 |
| US20230293549A1 (en) | 2023-09-21 |
| EP3253418A1 (en) | 2017-12-13 |
| AU2016214996B2 (en) | 2021-03-04 |
| JP2023078301A (ja) | 2023-06-06 |
| EP4059522A1 (en) | 2022-09-21 |
| IL302203A (en) | 2023-06-01 |
| JP2018504420A (ja) | 2018-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250325562A1 (en) | Intravenous Ganaxolone Formulations and Methods of Use in Treating Status Epilepticus and Other Seizure Disorders | |
| US20230181600A1 (en) | Injectable neurosteroid formulations containing nanoparticles | |
| US10391105B2 (en) | Methods of treating certain depressive disorders and delirium tremens | |
| CN1270718C (zh) | 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用 | |
| US20180296487A1 (en) | Sustained release injectable neurosteroid formulations | |
| JP2019537565A (ja) | 脳波（ｅｅｇ）バーストサプレッションをもたらすために神経ステロイドを投与する方法 | |
| EP4087569A1 (en) | Methods of administering nalbuphine | |
| WO2024020598A1 (en) | Methods of administering nalbuphine |